An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
← catalyst calendarNCT07438405 · readout in 528 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
8
Countries
Poland, Spain, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-07 | actual | When the study began enrolling |
| Primary completion | 2028-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Thyroid Eye Disease
Intervention
- Drug: AMG 732
Primary outcome
what the primary-completion date above is the date OFNumber of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent Trial
measured Week 24
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed